302 related articles for article (PubMed ID: 27977313)
1. Thioredoxin reductase inhibitors: a patent review.
Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin reductase inhibitors: updated patent review (2017-present).
Chupakhin E; Krasavin M
Expert Opin Ther Pat; 2021 Aug; 31(8):745-758. PubMed ID: 33666133
[No Abstract] [Full Text] [Related]
3. Small molecule inhibitors of mammalian thioredoxin reductase.
Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update.
Zhang J; Zhang B; Li X; Han X; Liu R; Fang J
Med Res Rev; 2019 Jan; 39(1):5-39. PubMed ID: 29727025
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin reductase as a pharmacological target.
Bjørklund G; Zou L; Wang J; Chasapis CT; Peana M
Pharmacol Res; 2021 Dec; 174():105854. PubMed ID: 34455077
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase as a pathophysiological factor and drug target.
Becker K; Gromer S; Schirmer RH; Müller S
Eur J Biochem; 2000 Oct; 267(20):6118-25. PubMed ID: 11012663
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.
Liu X; Pietsch KE; Sturla SJ
Chem Res Toxicol; 2011 May; 24(5):726-36. PubMed ID: 21443269
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
12. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
Zhang J; Yao J; Peng S; Li X; Fang J
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
[TBL] [Abstract][Full Text] [Related]
13. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
14. A diterpenoid derivate compound targets selenocysteine of thioredoxin reductases and induces Bax/Bak-independent apoptosis.
Liu J; Mu C; Yue W; Li J; Ma B; Zhao L; Liu L; Chen Q; Yan C; Liu H; Hao X; Zhu Y
Free Radic Biol Med; 2013 Oct; 63():485-94. PubMed ID: 23732520
[TBL] [Abstract][Full Text] [Related]
15. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.
Gandin V; Fernandes AP
Molecules; 2015 Jul; 20(7):12732-56. PubMed ID: 26184149
[TBL] [Abstract][Full Text] [Related]
16. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic.
Ren X; Zou L; Lu J; Holmgren A
Free Radic Biol Med; 2018 Nov; 127():238-247. PubMed ID: 29807162
[TBL] [Abstract][Full Text] [Related]
17. Thioredoxin reductase.
Mustacich D; Powis G
Biochem J; 2000 Feb; 346 Pt 1(Pt 1):1-8. PubMed ID: 10657232
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity.
Davioud-Charvet E; McLeish MJ; Veine DM; Giegel D; Arscott LD; Andricopulo AD; Becker K; Müller S; Schirmer RH; Williams CH; Kenyon GL
Biochemistry; 2003 Nov; 42(45):13319-30. PubMed ID: 14609342
[TBL] [Abstract][Full Text] [Related]
19. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity.
Gan FF; Kaminska KK; Yang H; Liew CY; Leow PC; So CL; Tu LN; Roy A; Yap CW; Kang TS; Chui WK; Chew EH
Antioxid Redox Signal; 2013 Oct; 19(11):1149-65. PubMed ID: 23311917
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro inhibition of mice thioredoxin reductase by methylmercury.
Wagner C; Sudati JH; Nogueira CW; Rocha JB
Biometals; 2010 Dec; 23(6):1171-7. PubMed ID: 20717703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
